CClinicalTrials.gg
CompletedNCT06194357Updated Jul 6, 2026

Integrated Mindfulness-based Health Qigong Intervention for COVID-19 Survivors and Caregivers

An interventional study of Mindfulness-based Health Qigong Intervention in COVID-19 Infection, sponsored by TSANG Hector Wing-Hong. Completed at 2 sites in Hong Kong. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by TSANG Hector Wing-Hong · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Nov 2022, registered Jan 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study examines the effectiveness of a 16-week Integrated Mindfulness-based Health Qigong (iMBHQ) program, delivered via a mobile application, in improving the mental and physical well-being of COVID-19 survivors, their caregivers, and the general public. We hypothesize that participants in the iMBHQ group will demonstrate significant reductions in stress, depression, and anxiety compared to a control group receiving treatment-as-usual. This parallel-group randomized controlled trial aims to recruit 600 participants (200 COVID-19 survivors, 200 caregivers, and 200 individuals from the general public). Effectiveness is evaluated at baseline, 8 weeks, 16 weeks, 6 months, and 12 months post-intervention, using standardized psychological and physical health assessments.

Read the detailed description

Background \& Objective The COVID-19 pandemic has precipitated significant psychological challenges, including stress, anxiety, and depression, among COVID-19 survivors, their caregivers, and the general public. The primary objective of this study is to examine whether an Integrated Mindfulness-based Health Qigong (iMBHQ) program can improve the physical and psychological wellness of these three distinct populations within the community.

Study Design \& Participants This study employs a 3 × 2 factorial parallel-group randomized controlled trial design. The trial aims to recruit a total of 600 participants (200 COVID-19 survivors, 200 caregivers, and 200 individuals from the general public). Participants will be randomized into either the treatment group (receiving the 16-week iMBHQ program) or the control group (receiving treatment-as-usual).

Intervention Procedures Delivered via a tailor-made mobile application, the iMBHQ program combines Health Qigong (Baduanjin) and Mindfulness-Based Interventions (MBIs) to target both physical health and psychological distress. During Weeks 1-8, participants complete mindfulness-based sessions lasting 2 hours per week. During Weeks 9-16, they transition to practicing Qigong for 30 minutes per day, five days a week. To evaluate efficacy, outcome data will be collected at baseline, 8 weeks (inter-intervention), 16 weeks (post-intervention), 6 months, and 12 months post-intervention.

Outcome Measures \& Analysis Primary and secondary outcome measures include the Depression, Anxiety and Stress Scale (DASS-21), Multidimensional Assessment of Interoceptive Awareness (MAIA), 12-item Short Form Health Survey (SF-12), Rumination Reflection Questionnaire (RRQ), Hyperarousal Scale, and specific scales measuring COVID-19-related fear, stigma, and attitudes toward vaccination. Data will be analyzed using the Intention-to-Treat (ITT) principle, and linear mixed models will be utilized to examine treatment × group interactions.

02

Conditions studied

  • COVID-19 Infection

Keywords

  • COVID-19 Survivors
  • caregivers
  • mindfulness-based health Qigong intervention
  • physical wellness
  • psychological wellness
03

In context

COVID-19

7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.

This study's enrollment of 600 is above the median of 100 across 4,099 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

This is the only study on the registry with TSANG Hector Wing-Hong as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • COVID-19 survivors: people aged 18 years or above who were infected by COVID-19 (both symptomatic and asymptomatic) and clinically recovered
  • Caregivers of COVID-19 patients, including family members or medical professionals who have contacts with patients diagnosed COVID-19 aged 18 years or above
  • General healthy public aged 18 years or above

Exclusion criteria

Exclusion Criteria:

  • people diagnosed severe and/or chronic conditions that prevent the practice of Qigong (e.g., acute exacerbation of dyspnoea, severe cardiopulmonary disease) or mindfulness intervention,
  • people with severe psychiatric disorder
  • people who have regular psychiatric follow-ups
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (actual)

Study arms

  • Experimental
    Intervention group

    Intervention group will receive training on Qigong exercise and mindfulness.

    Other: Mindfulness-based Health Qigong Intervention

  • No intervention
    Control group

    Control group will not receive intervention.

Interventions

  • OtherMindfulness-based Health Qigong Intervention

    Participants are introduced the practice of the most essential skills, particularly mindfulness and the basic movements of Qigong. The intervention lasts 16 weeks and is divided into two sequential 8-week phases: Phase 1 (Weeks 1-8): Participants complete mindfulness-based sessions lasting 2 to 2.5 hours per week. They are also instructed to complete three self-practice sessions (5 to 10 minutes per session), scheduled flexibly at their convenience. Phase 2 (Weeks 9-16): Participants complete 40 sessions of Health Qigong (5 sessions per week, 30 minutes each). To verify compliance, participants must upload a 1-minute self-practice video to the mobile application each week.

06

What researchers measure

Primary outcomes

  1. Psychological Symptoms

    Depression, Anxiety and Stress Scale (DASS-12)

    Time frame: From baseline to 12 months post-intervention

Secondary outcomes

  1. Interoception, Quality of Life, Rumination, Hyperarousal, Fear and Stigma Towards COVID-19, Attitude toward rapid testing and vaccine

    Multidimensional Assessment of Interoceptive Awareness (MAIA); 12-item Short Form healthy survey (SF-12); Rumination Reflection Questionnaire (RRQ); Pre-sleep Arousal Scale (PSAS); COVID-19 Public Stigma Scale (PSS); Fear of COVID-19 Scale (FCV); Thought on Covid-19 vaccination (TCV).

    Time frame: From baseline to 12 months post-intervention

07

Study locations

2 sites
  • Princess Margaret Hospital
    Hong Kong, Hong Kong
  • The Hong Kong Polytechnic University
    Hong Kong, Hong Kong
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06194357
Lead sponsor
TSANG Hector Wing-Hong
Collaborators
Health and Medical Research Fund
Responsible party
TSANG Hector Wing-Hong (Professor, The Hong Kong Polytechnic University) — Sponsor-investigator
First posted
Jan 8, 2024
Start date
Nov 8, 2022
Primary completion
Mar 28, 2026
Completion
Mar 31, 2026
Last update
Jul 6, 2026

Study contacts

Wing Hong, Hector TSANG, Prof
principal investigator · Department of Rehabilitation Science, Faculty of Health and Social Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion